Logo image of KROS

KEROS THERAPEUTICS INC (KROS) Stock Fundamental Analysis

NASDAQ:KROS - US4923271013 - Common Stock

15.71 USD
+0.24 (+1.55%)
Last: 9/9/2025, 8:00:02 PM
15.89 USD
+0.18 (+1.15%)
After Hours: 9/9/2025, 8:00:02 PM
Fundamental Rating

5

Overall KROS gets a fundamental rating of 5 out of 10. We evaluated KROS against 541 industry peers in the Biotechnology industry. KROS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KROS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year KROS was profitable.
In the past year KROS had a positive cash flow from operations.
KROS had negative earnings in each of the past 5 years.
KROS had a negative operating cash flow in each of the past 5 years.
KROS Yearly Net Income VS EBIT VS OCF VS FCFKROS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With an excellent Return On Assets value of 2.48%, KROS belongs to the best of the industry, outperforming 90.39% of the companies in the same industry.
Looking at the Return On Equity, with a value of 2.66%, KROS belongs to the top of the industry, outperforming 91.50% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 0.03%, KROS belongs to the top of the industry, outperforming 89.46% of the companies in the same industry.
Industry RankSector Rank
ROA 2.48%
ROE 2.66%
ROIC 0.03%
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
KROS Yearly ROA, ROE, ROICKROS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

1.3 Margins

KROS has a Profit Margin of 8.06%. This is amongst the best in the industry. KROS outperforms 91.68% of its industry peers.
Looking at the Operating Margin, with a value of 0.13%, KROS belongs to the top of the industry, outperforming 89.46% of the companies in the same industry.
Industry RankSector Rank
OM 0.13%
PM (TTM) 8.06%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KROS Yearly Profit, Operating, Gross MarginsKROS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KROS is destroying value.
Compared to 1 year ago, KROS has more shares outstanding
KROS has more shares outstanding than it did 5 years ago.
KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KROS Yearly Shares OutstandingKROS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
KROS Yearly Total Debt VS Total AssetsKROS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 8.17 indicates that KROS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.17, KROS belongs to the best of the industry, outperforming 82.81% of the companies in the same industry.
KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.17
ROIC/WACC0
WACC9.59%
KROS Yearly LT Debt VS Equity VS FCFKROS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 21.11 indicates that KROS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 21.11, KROS belongs to the top of the industry, outperforming 95.19% of the companies in the same industry.
KROS has a Quick Ratio of 21.11. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 21.11, KROS belongs to the best of the industry, outperforming 95.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 21.11
Quick Ratio 21.11
KROS Yearly Current Assets VS Current LiabilitesKROS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

KROS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 106.04%, which is quite impressive.
KROS shows a strong growth in Revenue. In the last year, the Revenue has grown by 85190.84%.
KROS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.71% yearly.
EPS 1Y (TTM)106.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.2%
Revenue 1Y (TTM)85190.84%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%49002.7%

3.2 Future

KROS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.26% yearly.
KROS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 178.15% yearly.
EPS Next Y99.03%
EPS Next 2Y3.34%
EPS Next 3Y2.17%
EPS Next 5Y10.26%
Revenue Next Year33010%
Revenue Next 2Y189.4%
Revenue Next 3Y182.51%
Revenue Next 5Y178.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KROS Yearly Revenue VS EstimatesKROS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
KROS Yearly EPS VS EstimatesKROS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 50.68, the valuation of KROS can be described as expensive.
KROS's Price/Earnings ratio is rather cheap when compared to the industry. KROS is cheaper than 91.50% of the companies in the same industry.
When comparing the Price/Earnings ratio of KROS to the average of the S&P500 Index (27.07), we can say KROS is valued expensively.
The Forward Price/Earnings Ratio is negative for KROS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 50.68
Fwd PE N/A
KROS Price Earnings VS Forward Price EarningsKROS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, KROS is valued cheaper than 97.60% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.02
EV/EBITDA -31.15
KROS Per share dataKROS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y3.34%
EPS Next 3Y2.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KROS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEROS THERAPEUTICS INC

NASDAQ:KROS (9/9/2025, 8:00:02 PM)

After market: 15.89 +0.18 (+1.15%)

15.71

+0.24 (+1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners107.33%
Inst Owner Change-2.06%
Ins Owners0.83%
Ins Owner Change6.51%
Market Cap638.14M
Analysts78.82
Price Target23.46 (49.33%)
Short Float %12.54%
Short Ratio10.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)797.34%
Min EPS beat(2)34.17%
Max EPS beat(2)1560.5%
EPS beat(4)2
Avg EPS beat(4)393.23%
Min EPS beat(4)-13.69%
Max EPS beat(4)1560.5%
EPS beat(8)6
Avg EPS beat(8)199.13%
EPS beat(12)9
Avg EPS beat(12)134.95%
EPS beat(16)10
Avg EPS beat(16)103.11%
Revenue beat(2)2
Avg Revenue beat(2)4964.74%
Min Revenue beat(2)543.8%
Max Revenue beat(2)9385.68%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.17%
PT rev (3m)-10%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)1.48%
EPS NY rev (1m)92.91%
EPS NY rev (3m)97.99%
Revenue NQ rev (1m)18.36%
Revenue NQ rev (3m)67.07%
Revenue NY rev (1m)3.44%
Revenue NY rev (3m)36.77%
Valuation
Industry RankSector Rank
PE 50.68
Fwd PE N/A
P/S 2.74
P/FCF 12.02
P/OCF 11.59
P/B 0.9
P/tB 0.9
EV/EBITDA -31.15
EPS(TTM)0.31
EY1.97%
EPS(NY)-4.67
Fwd EYN/A
FCF(TTM)1.31
FCFY8.32%
OCF(TTM)1.36
OCFY8.63%
SpS5.73
BVpS17.4
TBVpS17.4
PEG (NY)0.51
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.48%
ROE 2.66%
ROCE 0.04%
ROIC 0.03%
ROICexc 0.76%
ROICexgc 0.76%
OM 0.13%
PM (TTM) 8.06%
GM N/A
FCFM 22.8%
ROA(3y)-35.3%
ROA(5y)-29.15%
ROE(3y)-38.86%
ROE(5y)-31.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 144.12%
Cap/Sales 0.84%
Interest Coverage 250
Cash Conversion 3291.87%
Profit Quality 282.75%
Current Ratio 21.11
Quick Ratio 21.11
Altman-Z 8.17
F-Score8
WACC9.59%
ROIC/WACC0
Cap/Depr(3y)214.84%
Cap/Depr(5y)203.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)106.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.2%
EPS Next Y99.03%
EPS Next 2Y3.34%
EPS Next 3Y2.17%
EPS Next 5Y10.26%
Revenue 1Y (TTM)85190.84%
Revenue growth 3Y-43.89%
Revenue growth 5Y-18.71%
Sales Q2Q%49002.7%
Revenue Next Year33010%
Revenue Next 2Y189.4%
Revenue Next 3Y182.51%
Revenue Next 5Y178.15%
EBIT growth 1Y100.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99.6%
EBIT Next 3Y16.61%
EBIT Next 5YN/A
FCF growth 1Y146.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y149.54%
OCF growth 3YN/A
OCF growth 5YN/A